Raunak Shrestha's Avatar

Raunak Shrestha

@raunakms.bsky.social

Research Scientist • PhD in Bioinformatics • Data Scientist • Cancer Genomics @UCSF | SanFran, USA 🧬💻🔬 🇳🇵 🇨🇦 🇺🇸

109 Followers  |  468 Following  |  2 Posts  |  Joined: 28.02.2025  |  1.4664

Latest posts by raunakms.bsky.social on Bluesky

Post image

WOW! visualizing #nucleosome via cryo-EM
Paper: Direct visualization and tracing of DNA fold in Drosophila embryo doi.org/10.1101/2022...

17.04.2025 21:21 — 👍 5    🔁 0    💬 0    📌 0
Post image

The Genomic Revolution would not have happened without #NIH Funding to support ... #FundScience

02.04.2025 01:45 — 👍 4    🔁 0    💬 0    📌 0
Prostate Cancer Foundation 2025 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below). • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. • Provide up to a total of $1 million per team. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application. • All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. Research proposals in the following topic areas are solicited: • Theranostics. • Drugging currently undruggable oncology targets: preventing progression to lethal disease. • Improved biotechnologies for precision medicine. • First-in-field immunotherapies for prostate cancer. • Artificial intelligence/machine learning to better inform patient outcomes. • Host microbiome and tumor metabolism.

Prostate Cancer Foundation 2025 PCF Challenge Awards For Metastatic, Lethal Prostate Cancer REQUEST FOR APPLICATIONS The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. PCF seeks high-risk, currently unfunded projects from academic institutions around the world. PCF Challenge Awards: • Composed of a team of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below). • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years. • Provide up to a total of $1 million per team. • Cover only direct research costs and travel to the Annual PCF Scientific Retreat. • Clinical trial direct costs are not allowed; however, correlative research to support high impact clinical trials for advanced prostate cancer is encouraged. IRB submission and preferably approval is desired at time of application. • All studies involving patients must include plans for including diverse participant populations with appropriate representation of ethnic and racial minority groups. Comprehensive statistical plans and power calculations are required. Research proposals in the following topic areas are solicited: • Theranostics. • Drugging currently undruggable oncology targets: preventing progression to lethal disease. • Improved biotechnologies for precision medicine. • First-in-field immunotherapies for prostate cancer. • Artificial intelligence/machine learning to better inform patient outcomes. • Host microbiome and tumor metabolism.

ANNOUNCEMENT: RFA for 2025 @PCFnews team science Challenge Award Applications, to support investigations of metastatic, lethal #ProstateCancer in 6 specified topic areas.

DEADLINE: May 5, 2025

Apply at: pcf.smartsimple.com

View the RFA: res.cloudinary.com/pcf/images/v...

20.03.2025 16:53 — 👍 3    🔁 2    💬 0    📌 0
Segger logo

Segger logo

Message passing intuition behind the segger’s link-prediction model and the network architecture

Message passing intuition behind the segger’s link-prediction model and the network architecture

1/ New preprint! 🍳

@elihei.bsky.social and our team at @embl.org , @dkfz.bsky.social, and @mskcancercenter.bsky.social built #segger - a fast, accurate cell segmentation tool for spatial transcriptomics that assigns transcripts to their cell origins!

doi.org/10.1101/2025...

18.03.2025 14:48 — 👍 65    🔁 22    💬 2    📌 4
Preview
MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC - Nature In a model of pancreatic ductal adenocarcinoma, extrachromosomal DNAs are shown to be a source of high-level focal amplification driving MYC heterogeneity and phenotypic adaptation.

Nature research paper: MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

https://go.nature.com/41IPJwX

12.03.2025 19:34 — 👍 33    🔁 11    💬 0    📌 0

@raunakms is following 20 prominent accounts